Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Are Buying Taro Pharmaceutical Industries Ltd. (TARO)

Page 1 of 2

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track more than 700 prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile gigantic failures like hedge funds’ recent losses in Valeant. Let’s take a closer look at what the funds we track think about Taro Pharmaceutical Industries Ltd. (NYSE:TARO) in this article.

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) was in 23 hedge funds’ portfolios at the end of September. TARO investors should be aware of an increase in support from the world’s most elite money managers lately. There were 20 hedge funds in our database with TARO positions at the end of the previous quarter. At the end of this article we will also compare TARO to other stocks, including Alexandria Real Estate Equities Inc (NYSE:ARE), WABCO Holdings Inc. (NYSE:WBC), and EQT GP Holdings LP (NYSE:EQGP) to get a better sense of its popularity.

Follow Taro Pharmaceutical Industries Ltd
Trade (TAROF) Now!

In today’s marketplace there are several tools stock traders have at their disposal to evaluate their holdings. Some of the most innovative tools are hedge fund and insider trading interest. Our researchers have shown that, historically, those who follow the top picks of the elite fund managers can beat the market by a very impressive margin (see the details here).

With all of this in mind, we’re going to analyze the new action surrounding Taro Pharmaceutical Industries Ltd. (NYSE:TARO).

How are hedge funds trading Taro Pharmaceutical Industries Ltd. (NYSE:TARO)?

At the Q3’s end, a total of 23 of the hedge funds tracked by Insider Monkey were long this stock, a change of 15% from one quarter earlier. With the smart money’s positions undergoing their usual ebb and flow, there exists a select group of key hedge fund managers who were boosting their holdings significantly (or already accumulated large positions).

According to Insider Monkey’s hedge fund database, Brian Sheehy’s Iszo Capital has the most valuable position in Taro Pharmaceutical Industries Ltd. (NYSE:TARO), worth close to $108.6 million, corresponding to 61.6% of its total 13F portfolio. The second largest stake is held by Renaissance Technologies, with a $60.8 million position; the fund has 0.1% of its 13F portfolio invested in the stock. Remaining professional money managers with similar optimism include Jonathan Savitz’s Greywolf Capital Management, Shashin Shah’s Think Investments and Andrew Feldstein and Stephen Siderow’s Blue Mountain Capital.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!